 This 2 arm study will assess the long term safety and efficacy of RO4607381 in patients with coronary heart disease or a coronary heart disease CHD risk equivalent who have completed study NC19453. Patients eligible to participate in the extension study will continue on the treatment they were originally assigned to ie RO4607381 900mg po or placebo daily, with concomitant daily atorvastatin 10 to 80mg po. The anticipated time on study treatment is 6 months post study NC19453, and the target sample size is approximately 100 individuals. 